Altogether, PKM2 represents a strong predictor for poor prognosis and drug resistance in breast cancer and targeting PKM2–c-Myc–survivin cascade could be a novel therapeutic strategy for breast cancer treatment, even tamoxifen resistant breast cancer. Here, MYC is linked to breast carcinoma.